Drug Search Results
More Filters [+]

Lapatinib

Alternative Names: lapatinib, tykerb, gw572016, tyverb
Latest Update: 2024-04-03
Latest Update Note: Clinical Trial Update

Product Description

Lapatinib is a small molecule inhibitor of several tyrosine kinase receptors involved in tumor cell growth that is used in the therapy of advanced breast cancer and other solid tumors. Lapatinib therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lapatinib)

Mechanisms of Action: ERBB2 Inhibitor,EGFR Inhibitor,TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified

Known Adverse Events: Diarrhea

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lapatinib

Countries in Clinic: China, Korea, Turkey, Unknown Location

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Breast Cancer

Phase 2: Intestinal Cancer|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ROME

P2

Active, not recruiting

Intestinal Cancer|Non-Small-Cell Lung Cancer|Breast Cancer

2023-09-07

COMPLETE

P3

Completed

Breast Cancer

2022-07-27

2005-000846-35

P2

Completed

Breast Cancer

2022-06-22

2017-001994-18

P3

Active, not recruiting

Breast Cancer

2019-11-17

Recent News Events